

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab (anti-PD-1)	[Red bar]			R/R cHL
	[Dark blue bar]			R/R cHL
BGB-10188 (PI3Kδ inhibitor) +/- Zanubrutinib	[Light blue bar]			B-cell malignancies
Sonrotoclax (Bcl-2 inhibitor) monotherapy	[Red bar]			B-cell malignancies
	[Red bar]			R/R CLL/SLL
	[Red bar]			R/R MCL
	[Yellow bar]			Waldenstrom macroglobulinemia
Sonrotoclax + Azacitidine +/- Posaconazole	[Dark blue bar]			Myeloid malignancies
Sonrotoclax + Dexamethasone +/- Carfilzomib	[Dark blue bar]			R/R multiple myeloma with t(11;14)
Sonrotoclax + Zanubrutinib	[Dark blue bar]			B-cell malignancies
BGB-16673 (BTK-targeted CDAC)	[Dark blue bar]			B-cell malignancies
	[Red bar]			B-cell malignancies
Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab	[Red bar]			R/R DLBCL
	[Red bar]			R/R DLBCL with CD79B
Zanubrutinib	[Teal bar]			Previously treated B-cell malignancies
	[Pink bar]			B-cell malignancies
Zanubrutinib + Lenalidomide +/- Rituximab	[Red bar]			R/R DLBCL
Zanubrutinib + Obinutuzumab	[Yellow bar]			R/R FL
Zanubrutinib + Rituximab	[Dark blue bar]			1L MCL
	[Yellow bar]			R/R MZL

Safety and efficacy have not been established for investigational products and/or uses.

CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PI3Kδ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

■ United States
 ■ Australia, China
 ■ China
■ Australia, US
 ■ Worldwide
 ■ Japan

FOR MORE INFORMATION, CONTACT: MEDICALINFORMATION@BEIGENE.COM

0120-BGB-A283-MRC-001 **November 2023**